FRAX597 2 mg | 99.75%
TargetMol
FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).
More Information Supplier PageFRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).
More Information Supplier PageDJ-V159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A).
More Information Supplier PageDJ-V159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A).
More Information Supplier PageDJ-V159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A).
More Information Supplier PageDJ-V159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A).
More Information Supplier PageCOTI-2, an orally available thiosemicarbazone, is an activator of mutant forms of the p53 protein with potential antineoplastic activity.
More Information Supplier PageCOTI-2, an orally available thiosemicarbazone, is an activator of mutant forms of the p53 protein with potential antineoplastic activity.
More Information Supplier PageCOTI-2, an orally available thiosemicarbazone, is an activator of mutant forms of the p53 protein with potential antineoplastic activity.
More Information Supplier PageCOTI-2, an orally available thiosemicarbazone, is an activator of mutant forms of the p53 protein with potential antineoplastic activity.
More Information Supplier PageHispidol ((Z)-Hispidol) is a potential therapeutic for inflammatory bowel disease; inhibits TNF-α induced adhesion of monocytes to colon epithelial cells with an IC50 of 0.50 μM.
More Information Supplier Page